Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Zhejiang Huahai gets exclusive rights to four biosimilars from Oncobiologics

Executive Summary

Oncobiologics Inc. (cancer treaments and immunotherapies) has granted Shanghai-based drug company Zhejiang Huahai Pharmaceuticals Co. Ltd. rights to develop, manufacture, and sell four biosimilar monoclonal antibodies. Huahai gets exclusive rights in China (and will manufacture the products at its biologics facility there), and will co-develop and commercialize with Oncobiologics in more than 30 developed countries, including the US, EU, Japan, Australia, and Canada.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register